Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. - Wikidata - awgldk - TriplyDB

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

http://www.wikidata.org/entity/Q33179389

about

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey Agalsidase alfa: a review of its use in the management of Fabry disease Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice.A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation Development of a highly sensitive immuno-PCR assay for the measurement of α-galactosidase A protein levels in serum and plasma Mannose 6-phosphate receptor and sortilin mediated endocytosis of α-galactosidase A in kidney endothelial cells Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid Study of urinary proteomes in Anderson-Fabry disease.Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.Experimental therapies in hypertrophic cardiomyopathy Individual organelle pH determinations of magnetically enriched endocytic organelles via laser-induced fluorescence detection The organizing potential of sphingolipids in intracellular membrane transport.Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).Advances in the management of Anderson-Fabry disease: enzyme replacement therapy.Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease.Enzyme replacement therapy for Fabry disease: some answers but more questions Preselective gene therapy for Fabry disease.Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer Update on role of agalsidase alfa in management of Fabry disease.Enzyme therapy for Pompe disease: from science to industrial enterprise.Fabry disease: recent advances in enzyme replacement therapy.Comparative study of structural changes caused by different substitutions at the same residue on α-galactosidase A.Carboxyl-terminal truncations alter the activity of the human α-galactosidase A Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease.Enzyme replacement therapy: conception, chaos and culmination.Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease.Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.Efficient uptake of recombinant α-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneys Cellular and tissue distribution of intravenously administered agalsidase alfa.Innate and Adaptive Immune Response in Fabry Disease Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

P2860

Q24533551-93FDDAFB-30CD-4F60-9DC7-75D3F6FB2195 Q28250905-C3BF6248-F91E-4293-A7AB-7FD9391BBC03 Q28274194-D866787F-9CA3-4010-9ABE-16852E9AA849 Q28345052-FDD3821D-F279-495C-A5BF-9843D4F5FDFA Q28348809-0541C9E6-5121-448A-A913-1E76F65257ED Q28367193-D16840B3-0D33-4CDB-9885-FCBD2C90D3CA Q28477142-BF248CA0-9F9C-441E-925B-7B680019A297 Q28507358-7937A7C3-6D4A-448D-8E16-E524D22630A3 Q28507844-0E240775-E883-4EAB-8C67-82D7FE5C0BC8 Q28535053-A506D741-61E6-41FE-8D9D-938D03127C91 Q28727768-A37063EF-5E2E-4BC9-B7BC-DC4BFAFEC2F6 Q30481028-F0861D9B-1435-4411-8B10-5A3B6694E45D Q30497736-8258504D-79DD-473B-B4B9-AEF279398F51 Q33721228-B80EECCF-C5A0-4BEF-B990-9AAFCF91A20D Q33818578-0BC07EF2-05EF-439B-BF11-A0288AF685B4 Q33997765-0CC295B3-BCBC-422C-88DE-43662E639AB6 Q34001694-82F8568E-6251-48F1-94EC-A30AF8CD586B Q34388106-8E573998-5862-4289-B7B3-23B70AC05BD2 Q34483749-57D286E0-9AE6-4261-8ED7-7A26160D875A Q34553589-C5E78C02-AF55-487A-BAC2-B5085BD03EBC Q34560688-F2A1CA35-2AE0-4ECD-BBA0-BA274828EB13 Q34659532-60F5240A-DE8C-4CE8-9D23-BADA35257743 Q34660894-87958841-9DDB-4D12-A2EE-9AD4FEF9FA5B Q34703815-ABDE340B-D3C2-4963-BED5-D0312B18DD51 Q34736973-0427D67E-79AB-487D-887F-11298C1B2067 Q34870564-76640AC2-6AEB-491F-95E8-9677463D1EC2 Q34883178-8371E4A5-4D30-4F28-AD1E-CA6B4A9EC463 Q34954692-74F6410B-D65A-4C50-89FB-ADBA9F45E997 Q34974879-AD091C6C-76FF-45A9-A780-8574CFAFC110 Q35080882-00CDE385-2B1E-453A-B119-34FF224A348D Q35125851-77B20FB7-5452-473E-8D2D-5CF923D0E349 Q35147741-8CE25918-3C14-4EEA-A272-DE1D1097DC40 Q35153236-44753604-83A5-4612-87A6-D32B41C221C0 Q35597858-55400499-0E1F-46DD-B5F8-CF02FCDD6EA5 Q35665871-19EF3E62-A382-4124-848E-3CDE8BCA64E3 Q35719001-37931E3B-C4B4-424D-B70B-9D0ACF3150BC Q35728693-43DCE22A-0061-48CE-AC8D-D7AC079CB548 Q35800976-4EC1111F-0876-4CEB-87F5-2D55016A59D2 Q35946763-1B72B058-F36D-46DA-9F51-ADED4B664B80 Q35994824-31C25D92-A1D4-4863-B63D-C0233613A3F8

P2860

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

http://www.wikidata.org/entity/Q33179389

description

2000 nî lūn-bûn

@nan

2000 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Infusion of alpha-galactosidas ...... n patients with Fabry disease.

@ast

Infusion of alpha-galactosidas ...... n patients with Fabry disease.

@en

type

label

Infusion of alpha-galactosidas ...... n patients with Fabry disease.

@ast

Infusion of alpha-galactosidas ...... n patients with Fabry disease.

@en

prefLabel

Infusion of alpha-galactosidas ...... n patients with Fabry disease.

@ast

Infusion of alpha-galactosidas ...... n patients with Fabry disease.

@en

P1433

Q33179389-B268F438-3C93-491F-9D2A-CF1E69621BB6

P1476

Q33179389-46186562-03DC-4509-81CC-0E7EF4CC22E3

P2093

Q33179389-19A81B32-C204-460C-AE9B-94E5D43E5B2A

Q33179389-23C4655F-4D8F-437D-820F-DD2ED4B68D78

Q33179389-3B25FF19-DA35-43F6-ABF0-7F8BE9551AC0

Q33179389-46224DE2-981C-45C9-82BE-1F206FB24208

Q33179389-498BAFDD-AF19-4B05-9BBA-AEE06DA3A9C4

Q33179389-4B3489F9-010F-419C-8CEE-7015D2C801E6

Q33179389-4E2B292C-68DB-4F16-9828-3653D137563B

Q33179389-53A39181-1655-41B6-9C45-BEDE41B483F2

Q33179389-66012F85-CA27-4E8D-8C2D-39539521E639

Q33179389-78F798A4-084F-40FD-8A0A-33D6BCF01491

P2860

Q33179389-02BFDA5C-5576-41EB-B787-08BB79C0E6BB

Q33179389-0851587A-F9CA-4A18-8195-31A921A32D6E

Q33179389-09BF0E71-4048-457D-9CE1-8E54BC0C50E8

Q33179389-10CB8F99-1C70-4C31-B643-540959E679FF

Q33179389-3C5ACFDC-4946-4BAA-A0F7-0DAE124B6E80

Q33179389-47DEF41F-B477-49F3-B0D2-55E54886B543

Q33179389-4CA7D90E-B9FF-412C-8987-C1F3B826D5FB

Q33179389-53D2602E-48D8-49EF-9416-5AF3A6A45756

Q33179389-64228A4B-0EAD-459A-95DA-7B98FEA5F7EC

Q33179389-8DA20796-6D20-4D0A-A38B-FD78E9C6BAD0

P304

Q33179389-21E0FFD1-BC5A-4027-A254-0D9DDE85964F

P31

Q33179389-071580DD-446F-4E69-B3EC-536D950A77A4

P356

Q33179389-B04F2216-82F1-44FF-AD6E-D6B7BE5B0C18

P407

Q33179389-AFFE0750-DB67-4E73-B3CD-394B9137EB0A

P433

Q33179389-B02BD543-EB80-4BEF-B797-CB53502CA417

P478

Q33179389-A720BD51-407D-47C0-9FFC-DA683D766F23

P577

Q33179389-82FD3A7E-9204-4426-B39D-B186861C1DC0

P5875

Q33179389-42FF6F85-BB89-4107-B516-344DC790E1E5

P698

Q33179389-10A5A621-9962-4ADF-BACF-00D409AEE04A

P932

Q33179389-BEE45CF4-EDCE-460E-BA02-25DACB7FE80F

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Infusion of alpha-galactosidas ...... n patients with Fabry disease.

@en

P2093

Anderson T

http://www.w3.org/2001/XMLSchema#string

Borowski M

http://www.w3.org/2001/XMLSchema#string

Brady RO

http://www.w3.org/2001/XMLSchema#string

Crutchfield K

http://www.w3.org/2001/XMLSchema#string

Daniel P

http://www.w3.org/2001/XMLSchema#string

Doo E

http://www.w3.org/2001/XMLSchema#string

Frei K

http://www.w3.org/2001/XMLSchema#string

Gillespie F

http://www.w3.org/2001/XMLSchema#string

Gunter K

http://www.w3.org/2001/XMLSchema#string

Jeffries NO

http://www.w3.org/2001/XMLSchema#string

P2860

Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

The biogenesis of lysosomes

Mannose 6-phosphate receptors in sorting and transport of lysosomal enzymes.

Anderson-Fabry disease: a histopathological study of three cases with observations on the mechanism of production of pain

Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes.

Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation.

Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome.

Uptake of radiolabeled galactosyl-(alpha1 goes to 4)-galactosyl-(beta1 goes to 4)-glucosylceramide by human serum lipoproteins in vitro.

Purification and properties of the two major isozymes of alpha-galactosidase from human placenta.

P304

365-370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.97.1.365

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2000-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51363946

http://www.w3.org/2001/XMLSchema#string

P698

10618424

http://www.w3.org/2001/XMLSchema#string

P932

26669

http://www.w3.org/2001/XMLSchema#string